PMID- 17931051
OWN - NLM
STAT- MEDLINE
DCOM- 20080107
LR  - 20221207
IS  - 1520-9156 (Print)
IS  - 1520-9156 (Linking)
VI  - 9
IP  - 5
DP  - 2007 Oct
TI  - Indicators for the efficacy of pioglitazone before and during treatment in 
      Japanese patients with type 2 diabetes.
PG  - 429-37
AB  - BACKGROUND: The aim of this study is to explore appropriate indicators for the 
      efficacy of pioglitazone (Pio) before and during treatment of Japanese patients 
      with type 2 diabetes mellitus (T2DM). METHODS: Forty-eight Japanese patients with 
      T2DM (22 men, 26 women, 60 +/- 2 years old) were enrolled and treated with 15 
      mg/day of Pio for 12 weeks. Before and after the treatment, various parameters 
      were evaluated regarding the efficacy of Pio. Patients who had a reduction in 
      hemoglobin A1c (HbA1c) of >1% after 12 weeks of treatment were defined as 
      responders. RESULTS: Twenty-two patients were classified as responders. In the 
      responder group, age, fasting plasma glucose (FPG), and percentage female were 
      significantly (P < 0.05) higher compared with the non-responder group. In 
      logistic regression analysis, female sex and higher FPG were selected as 
      explanatory variables for the efficacy of Pio. Furthermore, the change of HbA1c 
      (DeltaHbA1c) was positively correlated with that of fasting C-peptide level 
      (DeltaCPR) and log-transformed high-sensitivity C-reactive protein (Deltalog 
      HS-CRP), and negatively correlated with that of high-density lipoprotein 
      cholesterol (DeltaHDL-C) and log-transformed adiponectin (Deltalog AP). In 
      multiple stepwise regression analysis, DeltaCPR, Deltalog HS-CRP, and Deltalog AP 
      (or DeltaFPG) were selected as explanatory variables for DeltaHbA1c. CONCLUSIONS: 
      We concluded that Pio is likely to show favorable effects on blood glucose 
      control especially in female patients with higher FPG levels. Administration of 
      Pio ameliorates blood glucose control accompanied by the increase of AP and the 
      decrease of CPR or HS-CRP, suggesting that Pio exerts its beneficial effects 
      through the enhancement of AP, which leads to suppression of inflammation and 
      amelioration of insulin resistance.
FAU - Tajiri, Yuji
AU  - Tajiri Y
AD  - Endocrinology and Metabolism Division, Fukuoka Medical Association Hospital, 
      Fukuoka, Japan. tajiri@seijin.city.fukuoka.med.or.jp
FAU - Takei, Ryoko
AU  - Takei R
FAU - Mimura, Kazuo
AU  - Mimura K
FAU - Umeda, Fumio
AU  - Umeda F
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazolidinediones)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Glucose/metabolism
MH  - Blood Pressure
MH  - Body Mass Index
MH  - Child
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - Pioglitazone
MH  - Regression Analysis
MH  - Sex Characteristics
MH  - Thiazolidinediones/*therapeutic use
EDAT- 2007/10/13 09:00
MHDA- 2008/01/08 09:00
CRDT- 2007/10/13 09:00
PHST- 2007/10/13 09:00 [pubmed]
PHST- 2008/01/08 09:00 [medline]
PHST- 2007/10/13 09:00 [entrez]
AID - 10.1089/dia.2007.0204 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2007 Oct;9(5):429-37. doi: 10.1089/dia.2007.0204.